Evidence map›Paper›PMID 28822091›Full record

ArticleEndocrine2017

Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.

Erika Tarasco, Petra Seebeck, Svende Pfundstein, Adrian F Daly, Philippe J Eugster, Alan G Harris, Eric Grouzmann, Thomas A Lutz, Christina N Boyle

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Evaluation of a NewMolecules (Basel, Switzerland) · 2020
    Article
  3. A newEJNMMI research · 2020
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Erika TarascoInstitute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland.
Petra SeebeckZurich Integrative Rodent Physiology (ZIRP), University of Zurich, 8057, Zurich, Switzerland.
Svende PfundsteinZurich Integrative Rodent Physiology (ZIRP), University of Zurich, 8057, Zurich, Switzerland.
Adrian F DalyDepartment of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.
Philippe J EugsterLaboratoire des Catecholamines et Peptides, Service de Biomédecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Alan G HarrisDepartment of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.
Eric GrouzmannLaboratoire des Catecholamines et Peptides, Service de Biomédecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Thomas A LutzInstitute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland.
Christina N BoyleInstitute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland. boyle@vetphys.uzh.ch.
University of Zurich · CHUniversity Hospital of Lausanne · CHCentre Hospitalier Universitaire de Liège · BESwiss Integrative Center for Human Health · CHUniversity of Liège · BE

Funding

Swiss Commitee of Technology and Innovation 15808.1 PFLS-LS
6 · The paper itself

Abstract

purposeSomatostatin analogs are widely used to treat conditions associated with hormonal hypersecretion such as acromegaly and metastatic neuroendocrine tumors. First generation somatostatin analogs, such as octreotide and lanreotide, have high affinity for somatostatin receptor subtype 2 (SSTR2), but have incomplete efficacy in many patients. Pasireotide targets multiple SSTRs, having the highest affinity for SSTR5, but causes hyperglycemia and diabetes mellitus in preclinical and clinical studies. AP102 is a new somatostatin analogs with high affinity at both SSTR2 and SSTR5. We aimed to characterize the effects of AP102 vs. pasireotide on random and dynamic glucose levels, glucoregulatory hormone concentrations and growth axis measures in healthy Sprague-Dawley rats.

methodsThree doses of each compound were evaluated under acute conditions (1, 10, and 30 µg/kg s.c.), and two doses during a chronic (4-week) infusion (3 and 10 µg/kg/h s.c.).

resultsNeither acute nor chronic AP102 administration altered blood glucose concentrations or dynamic responses following an intraperitoneal glucose tolerance test. In contrast, acute and chronic pasireotide dosing increased random and post-intraperitoneal glucose tolerance test blood glucose measures, compared to vehicle-treated controls. Both AP102 and pasireotide acutely suppressed growth hormone levels, although insulin-like growth factor-1 and somatic growth was suppressed to a greater extent with pasireotide.

conclusionsAP102 is a new dual SSTR2/SSTR5-specific somatostatin analog that acutely reduces growth hormone but does not cause hyperglycemia during acute or chronic administration in a healthy rat model. Further studies in diabetic animals and in humans are necessary to determine the potential utility of AP102 in the clinical setting.

Indexed as

AnimalsGlucoseGlucose Tolerance TestGrowthGrowth HormoneHormonesInfusions, SubcutaneousInsulinMaleRatsRats, Sprague-DawleyReceptors, SomatostatinSomatostatinGlucoseGrowth HormoneHormonesInsulinpasireotideReceptors, SomatostatinSomatostatinsomatostatin receptor 5Sstr2 protein, ratAcromegalyDiabetesGrowth hormoneInsulin-like growth factor-1Somatostatin analogSomatostatin receptor

Identifiers

PMID28822091
OpenAlexW2748013394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.